TNGX
NASDAQ
$27.54
Tango Therapeutics Inc (TNGX)
Tango Therapeutics Inc. is a leading clinical-stage biotechnology firm at the forefront of cancer treatment innovation, specializing in synthetic lethality and targeted therapies. With a robust pipeline of promising drug candidates focused on precision oncology, the company is uniquely positioned to address critical unmet needs in cancer care. Strategic collaborations with top academic institutions bolster its research and development efforts, enhancing its ability to deliver transformative therapeutic solutions. Tango Therapeutics aims to significantly improve patient outcomes and redefine treatment paradigms in oncology, making it a compelling investment opportunity in the biopharmaceutical landscape.
Sector:
Healthcare
Industry:
Biotechnology
Buy
Target: $44.33 (+60.97%)
Market Cap
$4.36B
Profit Margin
29.5%
Free Cash Flow Yield
-3.27%
Beta (5Y)
1.39
Price Chart
Valuation
Market Cap$4.36B
P/S86.42
P/B12.33
Profitability
Total Revenue (TTM)$57M
Gross Profit (TTM)-$72M
EBITDA-$115M
Profit Margin29.5%
Operating Margin26.2%
EPS-$0.81
Financial Health
Free Cash Flow Yield-3.27%
Growth & Risk
Revenue 5Y CAGR+17.63%
Beta (5Y)1.39
Sharpe Ratio1.80